Inocras, AimedBio Partner to Advance ADC Precision Oncology Development

Inocras Inc. and AimedBio have entered into a strategic partnership focused on using whole genome sequencing and multi-omics data to accelerate the development of antibody-drug conjugates, or ADCs, for cancer treatment.

The collaboration brings together Inocras’ cancer whole genome sequencing platform and AimedBio’s precision oncology and ADC development programs. As part of the agreement, South Korea-based AimedBio has made a strategic equity investment in U.S.-based precision medicine company Inocras. The companies have also signed a joint research agreement to integrate Inocras’ genomic analysis capabilities into AimedBio’s ongoing and future clinical programs.

Under the partnership, AimedBio will use Inocras’ whole genome sequencing, cancer intelligence platform and multi-omics analysis tools across its ADC clinical trials. The companies aim to identify cancer biomarkers, improve patient selection, support patient stratification and discover potential new therapeutic targets for oncology drug development.

Antibody-drug conjugates are a rapidly expanding class of targeted cancer therapies that combine a monoclonal antibody with a cytotoxic drug. These treatments are designed to deliver cancer-killing payloads directly to tumor cells while reducing exposure to healthy tissue. However, identifying which patients are most likely to respond to a specific ADC remains a major challenge in clinical development.

The companies believe comprehensive cancer whole genome data could help address that challenge by providing a deeper view of tumor biology. By analyzing genomic changes, molecular signatures and other multi-omics data, researchers may be able to identify biomarkers associated with treatment response, resistance and disease progression.

Inocras said its technology is designed to move beyond cancer diagnosis and support decision-making throughout the drug development process. The company’s cancer intelligence platform combines whole genome sequencing data with advanced computational analysis to generate insights that can support precision medicine, clinical trial design and oncology drug discovery.

Jehee Suh, chief executive officer of Inocras, said the partnership demonstrates how cancer whole genome sequencing can play a larger role in the development of new cancer treatments. He said integrating the company’s platform into active clinical trials could help accelerate precision oncology research while identifying patients who may benefit most from specific therapies.

AimedBio Chief Executive Officer Nam-Gu Her said patient identification is becoming increasingly important as competition in the ADC drug development market intensifies. He said Inocras’ genomic capabilities could support biomarker discovery, patient stratification and the identification of next-generation cancer targets.

Beyond clinical research, the companies plan to explore commercial opportunities that combine AimedBio’s precision drug screening business with Inocras’ diagnostic platform. The potential collaboration could support the global expansion of precision oncology services and help pharmaceutical companies use genomic data more effectively in cancer drug development.

The partnership reflects the growing use of whole genome sequencing, multi-omics analysis and biomarker-driven clinical trials in oncology. As drug developers seek to improve clinical trial success rates and develop more targeted cancer therapies, genomic data is expected to become increasingly important in selecting patients, identifying treatment opportunities and advancing personalized cancer care.